These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 29477409

  • 1. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
    Tsai YC, Chen WY, Abou-Kheir W, Zeng T, Yin JJ, Bahmad H, Lee YC, Liu YN.
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
    [Abstract] [Full Text] [Related]

  • 2. ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer.
    Fararjeh AS, Liu YN.
    Int J Mol Sci; 2019 Jun 08; 20(11):. PubMed ID: 31181727
    [Abstract] [Full Text] [Related]

  • 3. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY, Tsai YC, Yeh HL, Suau F, Jiang KC, Shao AN, Huang J, Liu YN.
    Sci Signal; 2017 Aug 15; 10(492):. PubMed ID: 28811384
    [Abstract] [Full Text] [Related]

  • 4. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J, Rupf B, Maiwald C, Baniahmad A.
    Mol Cell Biochem; 2016 Oct 15; 421(1-2):139-47. PubMed ID: 27562825
    [Abstract] [Full Text] [Related]

  • 5. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M, Itsumi M, Takeuchi A, Imada K, Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S.
    Endocr Relat Cancer; 2015 Dec 15; 22(6):889-900. PubMed ID: 26311513
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z, He L.
    Biochem Biophys Res Commun; 2015 Nov 13; 467(2):310-5. PubMed ID: 26435505
    [Abstract] [Full Text] [Related]

  • 7. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages.
    Lee GT, Kwon SJ, Kim J, Kwon YS, Lee N, Hong JH, Jamieson C, Kim WJ, Kim IY.
    Br J Cancer; 2018 Mar 06; 118(5):670-678. PubMed ID: 29381686
    [Abstract] [Full Text] [Related]

  • 8. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY, Zeng T, Wen YC, Yeh HL, Jiang KC, Chen WH, Zhang Q, Huang J, Liu YN.
    Cancer Lett; 2019 Jan 06; 440-441():35-46. PubMed ID: 30312731
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The transcription factor SPDEF suppresses prostate tumor metastasis.
    Steffan JJ, Koul S, Meacham RB, Koul HK.
    J Biol Chem; 2012 Aug 24; 287(35):29968-78. PubMed ID: 22761428
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Regulation of SPDEF expression by DNA methylation in advanced prostate cancer.
    Vatanmakanian M, Steffan JJ, Koul S, Ochoa AC, Chaturvedi LS, Koul HK.
    Front Endocrinol (Lausanne); 2023 Aug 24; 14():1156120. PubMed ID: 37900138
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.
    Cheng XH, Black M, Ustiyan V, Le T, Fulford L, Sridharan A, Medvedovic M, Kalinichenko VV, Whitsett JA, Kalin TV.
    PLoS Genet; 2014 Sep 24; 10(9):e1004656. PubMed ID: 25254494
    [Abstract] [Full Text] [Related]

  • 17. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, Palapattu GS.
    Neoplasia; 2015 Jun 24; 17(6):490-6. PubMed ID: 26152357
    [Abstract] [Full Text] [Related]

  • 18. Indole-3-carbinol and 3',3'-diindolylmethane modulate androgen's effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells.
    Kim EK, Kim YS, Milner JA, Wang TT.
    Cancer Prev Res (Phila); 2013 Jun 24; 6(6):519-29. PubMed ID: 23585426
    [Abstract] [Full Text] [Related]

  • 19. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
    Olsen JR, Azeem W, Hellem MR, Marvyin K, Hua Y, Qu Y, Li L, Lin B, Ke X, Øyan AM, Kalland K.
    BMC Cancer; 2016 Jul 04; 16():377. PubMed ID: 27378372
    [Abstract] [Full Text] [Related]

  • 20. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.
    Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, Balk S, Lee GS, Kantoff PW.
    Oncogene; 2014 May 22; 33(21):2790-800. PubMed ID: 23770851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.